Oncology Room
In this room you can find updates and expert discussions in oncology.
SMC accepts acalabrutinib for chronic lymphocytic leukaemia (restricted use)
Acalabrutinib is recommended as monotherapy under two indications.
SMC accepts treatment for relapsed and refractory multiple myeloma (restricted use)
Isatuximab accepted in combination with pomalidomide and dexamethasone for patients receiving fourth-line therapy.
#VisualAbstract Rituximab plus high-dose chemotherapy (MegaCHOEP) show similar long-term efficacy to conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma